Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2017-03-30 Annual Report
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Full Year Statutory Accounts 59 pages 921.5KB
Annual Report Classification · 100% confidence The document is titled 'Annual Financial Report 2016' for Lifespot Health Limited and its controlled entities. It contains detailed sections such as Operational and Financial Review, Directors' Report, Financial Position, Business Model and Objectives, Directors' Information, and Auditor's Independence Declaration. The content includes comprehensive financial data, business activities, strategic focus, and governance information for the financial period ended 31 December 2016. The length of the document is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of detailed financial statements and management discussion confirms it is an official yearly report covering company activity and full financial performance. Therefore, the document fits the definition of an Annual Report (10-K). FY 2016
2017-03-30 English
Exploring opportunities in Medicinal Cannabis 1 pag
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated March 28, 2017, providing an update on Lifespot Health Limited exploring opportunities in the medicinal cannabis sector. It discusses the company's strategic direction and ongoing discussions but does not contain financial statements, detailed financial data, or regulatory filings. The document is relatively short (2088 characters) and serves as a market update rather than a formal report or regulatory filing. It does not announce voting results, management changes, or capital activities. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous announcements that do not fit other specific categories.
2017-03-27 English
Lifespot Health wins major contract & strategic b2b partner 3 pages 62.7KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated March 8, 2017, from Lifespot Health Limited. It details a new business contract and strategic partnership with Beurer GmbH, focusing on software development for medical devices. The content is a corporate update about a new contract and partnership, not a financial report, earnings release, or regulatory filing. It does not contain financial statements, voting results, management changes, or legal proceedings. The document is a typical corporate announcement about business development and partnerships, which fits best under Capital/Financing Update (CAP) as it relates to strategic business growth and partnership agreements that could impact company capital or business operations. The document length is 8513 characters, sufficient for a substantive announcement rather than a brief notice. Therefore, the most appropriate classification is CAP with high confidence.
2017-03-07 English
Change of Registered Office 1 page 39.2KB
Regulatory Filings Classification · 95% confidence The document is a short announcement dated March 3, 2017, regarding a change of the registered office address of Lifespot Health Limited. It contains no financial data, no discussion of financial results, no regulatory certifications, or detailed report content. The document is brief (1241 characters) and serves as a notification of a corporate administrative change. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like management changes (MANG) or capital changes (SHA).
2017-03-02 English
Preliminary Final Report 9 pages 142.3KB
Annual Report Classification · 95% confidence The document is titled as a Preliminary Final Report for the year ending 31 December 2016, with detailed financial statements including profit and loss, statement of financial position, cash flows, movements in equity, and segment details. It includes comprehensive financial data for the full fiscal year, acquisition details, and notes on accounting standards. The document is over 13,000 characters, indicating it is a full report rather than a brief announcement. It is not a certification or a short announcement but a substantive financial report. The presence of detailed financial statements and the term 'Preliminary Final Report' aligns with an Annual Report or equivalent comprehensive yearly financial report. Therefore, the document fits best under the Annual Report (10-K) category. FY 2016
2017-02-28 English
Lifespot Health to enter coagulation home monitoring market 3 pages 75.6KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated February 3, 2017, from Lifespot Health Ltd. It discusses the company's subsidiary BodyTel integrating a new Bluetooth-enabled PT/INR device from Roche into its telemedical platform. The content focuses on a product and market update, describing the new device, its benefits, and the company's strategy. There are no financial statements, earnings data, regulatory certifications, or voting results. The document is approximately 9,930 characters, which is substantial but does not contain financial report data or management discussion. It is clearly an announcement about a new product integration and market segment entry, which fits best under Capital/Financing Update (CAP) as it relates to business development and strategic product integration announcements. It is not a report publication announcement or regulatory filing as it contains substantive business update information. Therefore, the most appropriate classification is CAP with high confidence.
2017-02-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.